Work

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Year: 2012

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-012-9843-5

Authors: Christophe Massard, Jane Margetts, Nadia Amellal, Yvette Drew, Ratislav Bahleda, Peter Stevens, Jean Pierre Armand, Hilary Calvert, Jean Charles Soria, Cinthya Coronado, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Carlos Fernández-Teruel, Ruth Plummer

Institutions: Institut Gustave Roussy, Freeman Hospital, PharmaMar (Spain)

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Multiple Sclerosis Society, National Cancer Institute

OpenAlex ID: W2005337156

FWCI: 1.632

Cites: 22

Cited by: 18

Related to: 10